Actelion may have a blockbuster on the decline--but it's also got two new launches that are keeping it in the game. For 2015, the Swiss company reported sales that were in line with analyst expectations and core earnings that beat them. Sales climbed 4% year over year to hit CHF 2.04 billion, while earnings rose to CHF 814 million ($827.24 million), besting predictions of CHF 813 million.
Actelion, the standard bearer in treatments for pulmonary arterial hypertension, is scouting for new disease areas as it rolls out its next potential blockbuster, hoping to keep up its pace of growth by pivoting away from its home base.
Actelion CEO Jean-Paul Clozel has dismissed the possibility of making a bid to buy Basilea Pharmaceutica. The comment quashed speculation that Actelion and Basilea could find solutions to their respective challenges by merging.
Actelion thinks it can reach blockbuster heights with new pulmonary arterial hypertension (PAH) treatment Uptravi, approved by the FDA last month and launched earlier this week. And a price tag between $160,000 and $170,000 will certainly help it get there.
Actelion predicts it'll have a difficult time competing against its rivals for M&A targets going forward. But never fear. The company will have plenty to plow into its own development work thanks to its hefty price tag on new pulmonary arterial hypertension med Uptravi, execs said Tuesday.
Actelion has been laboring to fill the void left by declining sales of aged pulmonary arterial hypertension (PAH) med Tracleer. And now, it has another tool to work with.
Swiss biotech Actelion extended its lead in the pulmonary arterial hypertension market, picking up FDA approval for a follow-on treatment that should help ward off mounting competition in the space.
Back in 2013, Actelion launched Opsumit, a new-and-improved pulmonary arterial hypertension drug it hoped would help make up sales for its aging Tracleer. And so far, everything is going according to plan.
Fast-growing biotech Actelion said it's not desperate for a big deal but hasn't ruled out its reported $2.5 billion effort to snatch up the smaller ZS Pharma.
Swiss biotech Actelion is discussing a $2.5 billion buyout of ZS Pharma, it confirmed Thursday, sending shares of its target soaring.